Advancing MDS Care: Navigating Challenges and Exploring the Patient Experience

home / peer-exchange / advancing-mds-care-navigating-challenges-and-exploring-the-patient-experience

Expert perspectives surrounding the management of patients diagnosed with advancing myelodysplastic syndrome.

Episodes

Advances in MDS Classification and Molecular Understanding

August 27th 2024EP. 1: Advances in MDS Classification and Molecular Understanding

Ryan Haumschild, PharmD, MS, MBA;James McCloskey, MD ;Amer Zeidan, MD;Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ;Tracey Iraca

After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding.

Choosing MDS Therapies: Risk-Based Approaches

August 27th 2024EP. 2: Choosing MDS Therapies: Risk-Based Approaches

Ryan Haumschild, PharmD, MS, MBA;James McCloskey, MD ;Amer Zeidan, MD;Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ;Tracey Iraca

Medical experts discuss risk-based approaches to choosing MDS therapies.

Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

September 3rd 2024EP. 3: Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

Ryan Haumschild, PharmD, MS, MBA;James McCloskey, MD ;Amer Zeidan, MD;Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ;Tracey Iraca

Medical experts offer insights on the COMMANDS trial findings.

ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

September 3rd 2024EP. 4: ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

Ryan Haumschild, PharmD, MS, MBA;James McCloskey, MD ;Amer Zeidan, MD;Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ;Tracey Iraca

Medical experts discuss the data gathered from the ASCERTAIN trial.

Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

September 10th 2024EP. 5: Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

Ryan Haumschild, PharmD, MS, MBA;James McCloskey, MD ;Amer Zeidan, MD;Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ;Tracey Iraca

Medical experts discuss convenience and efficacy in higher-risk MDS regarding oral vs injectable HMAs.

HMA Persistence and Effectiveness in Higher Risk MDS

September 10th 2024EP. 6: HMA Persistence and Effectiveness in Higher Risk MDS

Ryan Haumschild, PharmD, MS, MBA;James McCloskey, MD ;Amer Zeidan, MD;Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ;Tracey Iraca

Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.

Innovations and Future Directions in Higher Risk MDS Treatments

September 17th 2024EP. 7: Innovations and Future Directions in Higher Risk MDS Treatments

Ryan Haumschild, PharmD, MS, MBA;James McCloskey, MD ;Amer Zeidan, MD;Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ;Tracey Iraca

Medical experts discuss innovations and future directions in treatments for higher-risk MDS.

Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

September 17th 2024EP. 8: Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

Ryan Haumschild, PharmD, MS, MBA;James McCloskey, MD ;Amer Zeidan, MD;Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ;Tracey Iraca

Medical experts discuss innovations and future directions in treatments for higher-risk MDSMedical experts offer patient perspectives on advantages and disadvantages of using oral HMAs vs injectable HMAs.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo